NasdaqGS:ABUS

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in the United States. More Details


Snowflake Analysis

Flawless balance sheet with limited growth.


Similar Companies

Share Price & News

How has Arbutus Biopharma's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ABUS's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

4.3%

ABUS

-2.4%

US Biotechs

-4.6%

US Market


1 Year Return

227.1%

ABUS

26.7%

US Biotechs

11.5%

US Market

Return vs Industry: ABUS exceeded the US Biotechs industry which returned 26.7% over the past year.

Return vs Market: ABUS exceeded the US Market which returned 11.5% over the past year.


Shareholder returns

ABUSIndustryMarket
7 Day4.3%-2.4%-4.6%
30 Day-4.0%-1.7%-0.9%
90 Day-32.3%-3.0%2.2%
1 Year227.1%227.1%28.9%26.7%14.0%11.5%
3 Year-46.1%-46.1%18.2%12.3%34.5%25.6%
5 Year-52.1%-52.1%7.1%-0.6%73.0%53.6%

Price Volatility Vs. Market

How volatile is Arbutus Biopharma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Arbutus Biopharma undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Arbutus Biopharma is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Arbutus Biopharma has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

Future Growth

How is Arbutus Biopharma forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

8.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ABUS is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ABUS is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ABUS is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ABUS's revenue (41.4% per year) is forecast to grow faster than the US market (10% per year).

High Growth Revenue: ABUS's revenue (41.4% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ABUS's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Arbutus Biopharma performed over the past 5 years?

1.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ABUS is currently unprofitable.

Growing Profit Margin: ABUS is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ABUS is unprofitable, but has reduced losses over the past 5 years at a rate of 1.3% per year.

Accelerating Growth: Unable to compare ABUS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ABUS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-7.1%).


Return on Equity

High ROE: ABUS has a negative Return on Equity (-206.23%), as it is currently unprofitable.


Next Steps

Financial Health

How is Arbutus Biopharma's financial position?


Financial Position Analysis

Short Term Liabilities: ABUS's short term assets ($85.5M) exceed its short term liabilities ($6.3M).

Long Term Liabilities: ABUS's short term assets ($85.5M) exceed its long term liabilities ($25.8M).


Debt to Equity History and Analysis

Debt Level: ABUS is debt free.

Reducing Debt: ABUS had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ABUS has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: ABUS has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 15.6% each year


Next Steps

Dividend

What is Arbutus Biopharma current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ABUS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ABUS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ABUS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ABUS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ABUS's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.3yrs

Average management tenure


CEO

Bill Collier (60 yo)

1.33yrs

Tenure

US$2,334,185

Compensation

Mr. William H. Collier, also known as Bill, has experience as a senior executive in the pharmaceutical industry and previously served as President and General Manager, North America at ViiV Healthcare. At ...


CEO Compensation Analysis

Compensation vs Market: Bill's total compensation ($USD2.33M) is above average for companies of similar size in the US market ($USD1.34M).

Compensation vs Earnings: Insufficient data to compare Bill's compensation with company performance.


Leadership Team

NamePositionTenureCompensationOwnership
William Collier
President1.33yrsUS$2.33mno data
David Hastings
CFO & Chief Accounting Officer2.33yrsUS$1.01m0%
$ 0
Michael Sofia
Chief Scientific Officer5.75yrsUS$1.05m2.01%
$ 4.9m
Pam Murphy
Investor Relations Consultantno datano datano data
Elizabeth Howard
Executive VP4.58yrsUS$740.05kno data
Gaston Picchio
Chief Development Officer2yrsUS$1.78mno data
Michael McElhaugh
Chief Business Officer1.83yrsno data1.65%
$ 4.0m
R. Mackay-Dunn
Secretary10.42yrsno datano data

2.3yrs

Average Tenure

60yo

Average Age

Experienced Management: ABUS's management team is considered experienced (2.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
William Collier
President1.33yrsUS$2.33mno data
Richard Henriques
Independent Non-Executive Director5.58yrsUS$88.72k0.0012%
$ 2.9k
Daniel Burgess
Independent Director3.58yrsUS$78.72k0%
$ 0
Keith Manchester
Independent Non-Executive Director5.58yrsUS$71.22k0%
$ 0
Adrian Di Bisceglie
Member of Scientific Advisory Boardno datano datano data
Charles Rice
Member of Scientific Advisory Boardno datano datano data
James Meyers
Independent Director2yrsUS$88.72k0%
$ 0
William Symonds
Chairman of Scientific Advisory Board2yrsno datano data
Frank Torti
Independent Chairman of the Board of Directors1.92yrsUS$83.72k0%
$ 0
Fabien Zoulim
Member of Scientific Advisory Boardno datano datano data
Scott Biller
Member of Scientific Advisory Boardno datano datano data
Ulrike Protzer
Member of Scientific Advisory Boardno datano datano data

2.0yrs

Average Tenure

56.5yo

Average Age

Experienced Board: ABUS's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 45.8%.


Top Shareholders

Company Information

Arbutus Biopharma Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Arbutus Biopharma Corporation
  • Ticker: ABUS
  • Exchange: NasdaqGS
  • Founded:
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$241.266m
  • Shares outstanding: 82.91m
  • Website: https://www.arbutusbio.com

Number of Employees


Location

  • Arbutus Biopharma Corporation
  • 701 Veterans Circle
  • Warminster
  • Pennsylvania
  • 18974
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ABUSNasdaqGS (Nasdaq Global Select)YesCommon SharesUSUSDMay 2007
I9DNDB (Deutsche Boerse AG)YesCommon SharesDEEURMay 2007

Biography

Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in t ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/28 23:58
End of Day Share Price2020/10/28 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.